Immunovant, Inc. (IMVT)

Market Cap	4.10B
Revenue (ttm)	n/a
Net Income (ttm)	-243.45M
Shares Out	145.29M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,079,132
Open	28.27
Previous Close	28.32
Day's Range	27.33 - 28.64
52-Week Range	15.12 - 45.58
Beta	0.70
Analysts	Strong Buy
Price Target	44.67 (+58.29%)
Earnings Date	May 20, 2024

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences L...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Peter Salzmann M.B.A., M.D.
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: IMVT

Analyst Forecast

According to 18 analysts, the average rating for IMVT stock is "Strong Buy." The 12-month stock price forecast is $44.67, which is an increase of 58.29% from the latest price.

Price Target

$44.67

(58.29% upside)

Analyst Consensus: Strong Buy